Hormone receptor positive breast cancer
Not recruitingEffect of PF-07850327 on Midazolam Pharmacokinetics in Healthy Adult Females (Non‑Childbearing) Relevant to ER+/HER2‑Positive Breast Cancer
Effect of PF-07850327 on Midazolam Pharmacokinetics in Healthy Adult Females (Non‑Childbearing) Relevant to ER+/HER2‑Positive Breast Cancer
- Disease:Hormone receptor positive breast cancer
- Substances:MidazolamVepdegestrant
Belgium- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:Midazolam
- Sponsor:Pfizer Inc.












